Menu
+
+
+
+
+
+
Gene editing company Editas Medicine Inc. (NASDAQ:EDIT) proposed to raise $50 million in a follow-on underwritten by Morgan Stanley. Editas, which proposed the...
BioCentury employs a fully integrated multimedia platform — including publications, video, online data solutions and conferences — to provide its audience with authoritative and up-to-date intelligence about corporate strategy, partnering, emerging technology, clinical data, public policy and the financial markets.
